REG - CRISM Therapeutics - European Patent Grant

CRISM' TherapeuticsAnnouncement

18/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241218:nRSR4653Qa&default-theme=true

RNS Number : 4653Q  CRISM Therapeutics Corporation  18 December 2024

The information contained within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulation (EU) No.
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act
2018. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

18 December 2024

 

 

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

 

European Patent Grant

 

CRISM Therapeutics Corporation (AIM: CRTX), the innovative UK drug delivery
company focused on the localised delivery of chemotherapy drugs, is pleased to
announce that it has been granted a European patent (EP4072552) by the
European Patent Office.

The patent relates to the Company's lead product, ChemoSeed®, for
chemotherapeutic drug implants and more, particularly, to biodegradable
chemotherapeutic drug implants comprising irinotecan.   ChemoSeed was
invented by Professor Chris McConville, CRISM's Chief Scientific Officer.

The patent covers the manufacturing processes for the preparation of these
chemotherapeutic drug implants and to their use in therapy, in particular in
treating brain tumours such as high grade glioma.  The Company believes that
local delivery of irinotecan directly to the brain tumour resection site could
improve therapeutic outcomes by allowing for the delivery of larger doses
directly to the tumour site, while reducing systemic concentrations and thus
alleviating the traditional side-effects.

The Company has patents submitted in other key jurisdictions and will update
the market as to their progress accordingly.

Commenting on the patent grant, CRISM CEO Andrew Webb said: "The granting of
this patent by the European patent office is a key milestone for CRISM and
further validates the novelty of ChemoSeed. Additionally, this provides CRISM
IP protection in one of our key markets whilst enhancing ChemoSeed's appeal to
potential commercial partners.   The Board believes that ChemoSeed could
improve therapeutic outcomes for brain tumour patients and we look forward to
demonstrating this as we prepare for a clinical trial in 2025."

-Ends-

 

 

Enquiries:

 

 Company                         Nomad and Broker                  Financial PR
 CRISM Therapeutics Corporation  S.P. Angel Corporate Finance LLP  Burson Buchanan
 Andrew Webb, CEO                Richard Morrison                  Mark Court / Jamie Hooper

 Chris McConville, CSO           Adam Cowl                         CRISM@buchanancomms.co.uk
 via Burson Buchanan             +44 (0) 20 3470 0470              +44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery
technology to improve the clinical performance of cancer treatments for solid
tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or
the resection margin following the removal of a tumour. This directs that
therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour
tissue or cover the entire resection margin. In the case of treating
high-grade glioma, ChemoSeeds can be implanted during surgery thereby
bypassing the blood brain barrier, which prevents other treatments from being
able to reach the tumour and be effective.

CRISM plans to submit a clinical trial application for ChemoSeed® in
high-grade glioma.  Based on preclinical data, the Tessa Jowell BRAIN MATRIX
Scientific Advisory Board has approved ChemoSeed in a phase II platform
clinical trial which is an efficient and cost-effective clinical development
opportunity.

For more information please visit: https://www.crismtherapeutics.com/
(https://www.crismtherapeutics.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  REAEAKAXFDELFFA